Static list review – October 2016
Decision to remain on the static guidance list
Febuxostat for the management of hyperuricaemia in people with gout was added to the static list in October 2011.
As the appraisal has been on the static list for more than 5 years, NICE has been gathering intelligence to ascertain whether there is any new evidence available relevant to this appraisal and whether this should be considered through the full review proposal process.
We have concluded that there has been no change in the evidence base that is likely to lead to a change in the existing recommendations.
As a result, we have decided that TA164 should remain on the static list and no further action is required at this time.
This page was last updated: